Medicare GLP-1 Plan Costs Insurers Billions; Novo Nordisk Challenges Eli Lilly Launch
Trump’s plan to cover GLP-1 weight-loss drugs for Medicare would cost insurers billions in year one, with $900 million saved covering just 4.4% of newly eligible patients and requiring 80% insurer opt-in. Novo Nordisk is countering as Eli Lilly readies its latest GLP-1 obesity drug, heightening market competition.
1. Medicare Coverage Proposal
In a proposed pilot program set to launch next year, the administration plans to cover GLP-1 weight-loss medications for Medicare enrollees with chronic conditions, potentially costing insurers billions in year one. Researchers estimate that negotiated price cuts would yield $900 million in savings but only cover 4.4% of newly eligible patients, while insurers must opt in by the 80% participation threshold by April 20 to trigger implementation.
2. Competitive Dynamics in the GLP-1 Market
Eli Lilly is preparing to launch its latest GLP-1 obesity drug, prompting Novo Nordisk to introduce countermeasures including pricing adjustments and marketing campaigns. The intensifying rivalry for market share in the GLP-1 space highlights potential pricing pressure and shifting dynamics as both companies target an expanding obesity treatment market.